RESOLIAN BUYS CHINA-BASED BIOANALYTICAL CRO DENALI MEDPHARMA

KUALA LUMPUR, Nov 2 (Bernama) -- Resolian, a global bioanalytical contract research organisation (CRO) specialising in drug metabolism and pharmacokinetics for small and large molecules has acquired China-based bioanalytical CRO, Denali Medpharma.

Resolian Chief Executive Officer (CEO), Patrick Bennett in a statement said the strategic addition of Denali will significantly enhanced the company’s capabilities and strengthened its position in the global market.

“Denali’s founders and core scientists are internationally recognised across pharmaceutical research and development analysis and we are particularly excited to add Denali’s oligo, mRNA, and liposomal expertise to Resolian’s portfolio of services.

“We look forward to leveraging our growing company’s strengths to continue driving innovation and creating lasting value for our clients and stakeholders,” added Bennett.

Meanwhile, Denali CEO, Min Meng said the company was founded by a group of United States (US)-trained bioanalytical experts in a state-of-the-art lab facility in China to provide exceptional service for domestic and international clients.

“The Denali team is thrilled to join Resolian. We look forward to continuing this track record and offering even greater capabilities and trial flexibility as part of Resolian.”

Currently operates bioanalysis laboratory in the US, the United Kingdom, Australia and China, Resolian can initiate a project on four continents and easily transfer validated methods across labs, allowing therapeutic trials to extend to virtually any destination without changing bioanalytical CROs.

-- BERNAMA